# Kyverna Therapeutics Inc. (KYTX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $8.25, market value $510 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Kyverna Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 3.1×**. The shares trade at 3.1× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -69.4%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -9.3%**. Earnings per share fell 9.3%.

## Financial health
- **Debt to equity: 0.11**. Debt is 0.11 times equity: a conservative balance sheet.
- **Current ratio: 7.75** (quick 7.75). Current assets cover the next year's liabilities 7.75 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Kyverna Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover Kyverna Therapeutics Inc.; the consensus is strong_buy, with an average price target of $30.40 (+268% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 127.3%** (YTD -12.2%, 3-mo 10.4%). The shares are up 127.3% over twelve months including dividends.
- **From 52-week high: -39.6%** (120.6% above the low). Trading 40% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 2.53** (volatility 101%). Beta of 2.53 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=KYTX · Page: https://foliofundamentals.com/stocks/kytx

Not investment advice.